Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD)

Nur Afiqah Mohamad, Vasudevan Ramachandran, Patimah Ismail, Hazlita Mohd Isa, Yoke Mun Chan, Nor Fariza Ngah, Norshakimah Md Bakri, Siew Mooi Ching, Fan Kee Hoo, Wan Aliaa Wan Sulaiman, Liyana Najwa Inche Mat, Mohd Hazmi Mohamed

Research output: Contribution to journalArticle

Abstract

Pharmacogenetic studies indicate that a variable response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular form of AMD (nAMD) may be due to polymorphisms in the complement factor H gene (CFH). This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with the baseline values. Genotyping of Y402H (rs1061170) polymorphism was performed using PCR-RFLP and the amplified product was digested with MluCI restriction enzyme. Association between the Y402H genotypes and response to treatment was determined by a logistic regression analysis of responder (n = 49) and non-responder (n = 84) group. Significantly worse mean BCVA was observed for the CC genotype compared to the TT + CT genotype in the total sample after 6-month follow-up (p = 0.018). Comparing the baseline and 6-month point measurements, improved mean BCVA was observed in responder group, while worse mean BCVA was recorded for non-responder group. However, our regression analysis, adjusted for confounding factors, showed no significant association between the Y402H genotypes and response to treatment in nAMD patients under the recessive model (p > 0.05). Overall, our results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population.

Original languageEnglish
Pages (from-to)260-267
Number of pages8
JournalBosnian Journal of Basic Medical Sciences
Volume18
Issue number3
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Complement Factor H
Macular Degeneration
Visual Acuity
Genotype
Genes
Vascular Endothelial Growth Factor A
Therapeutics
Regression Analysis
Intravitreal Injections
Restriction Fragment Length Polymorphisms
Ranibizumab
Logistic Models
Polymerase Chain Reaction
Injections
Enzymes
Population

Keywords

  • Age-related macular degeneration
  • AMD
  • CFH
  • Complement factor H
  • Ranibizumab
  • SNP
  • Treatment response
  • Y402H

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD). / Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Ismail, Patimah; Mohd Isa, Hazlita; Chan, Yoke Mun; Ngah, Nor Fariza; Bakri, Norshakimah Md; Ching, Siew Mooi; Hoo, Fan Kee; Sulaiman, Wan Aliaa Wan; Mat, Liyana Najwa Inche; Mohamed, Mohd Hazmi.

In: Bosnian Journal of Basic Medical Sciences, Vol. 18, No. 3, 01.01.2018, p. 260-267.

Research output: Contribution to journalArticle

Mohamad, NA, Ramachandran, V, Ismail, P, Mohd Isa, H, Chan, YM, Ngah, NF, Bakri, NM, Ching, SM, Hoo, FK, Sulaiman, WAW, Mat, LNI & Mohamed, MH 2018, 'Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD)', Bosnian Journal of Basic Medical Sciences, vol. 18, no. 3, pp. 260-267. https://doi.org/10.17305/bjbms.2018.2493
Mohamad, Nur Afiqah ; Ramachandran, Vasudevan ; Ismail, Patimah ; Mohd Isa, Hazlita ; Chan, Yoke Mun ; Ngah, Nor Fariza ; Bakri, Norshakimah Md ; Ching, Siew Mooi ; Hoo, Fan Kee ; Sulaiman, Wan Aliaa Wan ; Mat, Liyana Najwa Inche ; Mohamed, Mohd Hazmi. / Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD). In: Bosnian Journal of Basic Medical Sciences. 2018 ; Vol. 18, No. 3. pp. 260-267.
@article{bec8635144ee44f3a34600fb94739ca4,
title = "Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD)",
abstract = "Pharmacogenetic studies indicate that a variable response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular form of AMD (nAMD) may be due to polymorphisms in the complement factor H gene (CFH). This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with the baseline values. Genotyping of Y402H (rs1061170) polymorphism was performed using PCR-RFLP and the amplified product was digested with MluCI restriction enzyme. Association between the Y402H genotypes and response to treatment was determined by a logistic regression analysis of responder (n = 49) and non-responder (n = 84) group. Significantly worse mean BCVA was observed for the CC genotype compared to the TT + CT genotype in the total sample after 6-month follow-up (p = 0.018). Comparing the baseline and 6-month point measurements, improved mean BCVA was observed in responder group, while worse mean BCVA was recorded for non-responder group. However, our regression analysis, adjusted for confounding factors, showed no significant association between the Y402H genotypes and response to treatment in nAMD patients under the recessive model (p > 0.05). Overall, our results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population.",
keywords = "Age-related macular degeneration, AMD, CFH, Complement factor H, Ranibizumab, SNP, Treatment response, Y402H",
author = "Mohamad, {Nur Afiqah} and Vasudevan Ramachandran and Patimah Ismail and {Mohd Isa}, Hazlita and Chan, {Yoke Mun} and Ngah, {Nor Fariza} and Bakri, {Norshakimah Md} and Ching, {Siew Mooi} and Hoo, {Fan Kee} and Sulaiman, {Wan Aliaa Wan} and Mat, {Liyana Najwa Inche} and Mohamed, {Mohd Hazmi}",
year = "2018",
month = "1",
day = "1",
doi = "10.17305/bjbms.2018.2493",
language = "English",
volume = "18",
pages = "260--267",
journal = "Bosnian Journal of Basic Medical Sciences",
issn = "1512-8601",
publisher = "Association of Basic Medical Sciences Federation of Bosnia and Herzegovina",
number = "3",

}

TY - JOUR

T1 - Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (NAMD)

AU - Mohamad, Nur Afiqah

AU - Ramachandran, Vasudevan

AU - Ismail, Patimah

AU - Mohd Isa, Hazlita

AU - Chan, Yoke Mun

AU - Ngah, Nor Fariza

AU - Bakri, Norshakimah Md

AU - Ching, Siew Mooi

AU - Hoo, Fan Kee

AU - Sulaiman, Wan Aliaa Wan

AU - Mat, Liyana Najwa Inche

AU - Mohamed, Mohd Hazmi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pharmacogenetic studies indicate that a variable response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular form of AMD (nAMD) may be due to polymorphisms in the complement factor H gene (CFH). This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with the baseline values. Genotyping of Y402H (rs1061170) polymorphism was performed using PCR-RFLP and the amplified product was digested with MluCI restriction enzyme. Association between the Y402H genotypes and response to treatment was determined by a logistic regression analysis of responder (n = 49) and non-responder (n = 84) group. Significantly worse mean BCVA was observed for the CC genotype compared to the TT + CT genotype in the total sample after 6-month follow-up (p = 0.018). Comparing the baseline and 6-month point measurements, improved mean BCVA was observed in responder group, while worse mean BCVA was recorded for non-responder group. However, our regression analysis, adjusted for confounding factors, showed no significant association between the Y402H genotypes and response to treatment in nAMD patients under the recessive model (p > 0.05). Overall, our results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population.

AB - Pharmacogenetic studies indicate that a variable response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular form of AMD (nAMD) may be due to polymorphisms in the complement factor H gene (CFH). This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with the baseline values. Genotyping of Y402H (rs1061170) polymorphism was performed using PCR-RFLP and the amplified product was digested with MluCI restriction enzyme. Association between the Y402H genotypes and response to treatment was determined by a logistic regression analysis of responder (n = 49) and non-responder (n = 84) group. Significantly worse mean BCVA was observed for the CC genotype compared to the TT + CT genotype in the total sample after 6-month follow-up (p = 0.018). Comparing the baseline and 6-month point measurements, improved mean BCVA was observed in responder group, while worse mean BCVA was recorded for non-responder group. However, our regression analysis, adjusted for confounding factors, showed no significant association between the Y402H genotypes and response to treatment in nAMD patients under the recessive model (p > 0.05). Overall, our results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population.

KW - Age-related macular degeneration

KW - AMD

KW - CFH

KW - Complement factor H

KW - Ranibizumab

KW - SNP

KW - Treatment response

KW - Y402H

UR - http://www.scopus.com/inward/record.url?scp=85051084677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051084677&partnerID=8YFLogxK

U2 - 10.17305/bjbms.2018.2493

DO - 10.17305/bjbms.2018.2493

M3 - Article

C2 - 29579408

AN - SCOPUS:85051084677

VL - 18

SP - 260

EP - 267

JO - Bosnian Journal of Basic Medical Sciences

JF - Bosnian Journal of Basic Medical Sciences

SN - 1512-8601

IS - 3

ER -